Red cell alloimmunisation in patients with different types of infections

Dorothea Evers,1,2 Johanna G. van der Bom,1,3,* Janneke Tijmensen,1,2 Rutger A. Middelburg,1,3 Masja de Haas,1,2,4 Saurabh Zalpuri,1 Karen M. K. de Voogt,5 Daan van de Kerkhof,6 Otto Visser,7 Nathalie C. V. Pequériaux,8 Francisca Hudig9 and Jaap Jan Zwaginga1,2,*

1Center for Clinical Transfusion Research, Sanquin Research, 2Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, 3Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 4Department of Immunohaematology Diagnostics, Sanquin, Amsterdam, 5Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, 6Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, 7Department of Haematology, VU Medical Center, Amsterdam, 8Department of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, ’s-Hertogenbosch, and 9LabWest, Haga Teaching Hospital, The Hague, The Netherlands

Received 31 May 2016; accepted for publication 3 July 2016
Correspondence: Jaap Jan Zwaginga, Center for Clinical Transfusion Research, Sanquin Research, Plesmanlaan 1A, 2333 BZ, Leiden, The Netherlands.
E-mail: j.j.zwaginga@lumc.nl
*These authors contributed equally to this work.

Red cell alloimmunisation challenges the provision of compatible donor blood and, most importantly, might induce severe haemolytic transfusion reactions (Serious Hazards Of Transfusion [SHOT], 2014; Transfusion and Transplantation Reactions In Patients [TRIP], 2014). Consequently, some selected patients receive extensively matched blood (Dutch Institute for Healthcare Improvement [CBO], 2011; United Kingdom Blood Services, 2013). Despite the effectiveness of these risk-based matching practices (Vichinsky et al, 2001; Lasalle-Williams et al, 2011; Schonewille et al, 2015), non-selected patients do experience alloimmunisation-mediated complications (Harvey et al, 2014; TRIP, 2014; SHOT, 2015) warranting consideration of additional risk factors.

In addition to the chance of encountering a high immunogenic non-self antigen (Evers et al, 2016), clinical conditions affecting the recipient’s immune response

Summary

Red cell alloantigen exposure can cause alloantibody-associated morbidity. Murine models have suggested that inflammation modulates red cell alloimmunisation. This study quantifies alloimmunisation risks during infectious episodes in humans. We performed a multicentre case–control study within a source population of patients receiving their first and subsequent red cell transfusions during an 8-year follow-up period. Patients developing a first transfusion-induced red cell alloantibody (N = 505) were each compared with two similarly exposed, but non-alloimmunised controls (N = 1010) during a 5-week ‘alloimmunisation risk period’ using multivariate logistic regression analysis. Transfusions during ‘severe’ bacterial (tissue-invasive) infections were associated with increased risks of alloantibody development [adjusted relative risk (RR) 1/34, 95% confidence interval (95% CI) 0/97–1/85], especially when these infections were accompanied with long-standing fever (RR 3/06, 95% CI 1/57–5/96). Disseminated viral disorders demonstrated a trend towards increased risks (RR 2/41, 95% CI 0/89–6/53), in apparent contrast to a possible protection associated with Gram-negative bacteraemia (RR 0/58, 95% CI 0/13–1/14). ‘Simple’ bacterial infections, Gram-positive bacteraemia, fungal infections, maximum C-reactive protein values and leucocytosis were not associated with red cell alloimmunisation. These findings are consistent with murine models. Confirmatory research is needed before patients likely to develop alloantibodies may be identified based on their infectious conditions at time of transfusion.

Keywords: red blood cell alloimmunisation, blood transfusion, infections, inflammation, humans.
probably modulate alloimmunisation. Identification of such factors might enable allocating extensively matched blood principally to high-risk patients.

Experimentally induced inflammation has consistently been demonstrated as a major determinant of red cell alloimmunisation in mice (Hendrickson et al., 2006, 2007; Hendrickson, 2008; Smith et al., 2012). In line with this, pro-inflammatory conditions related to sickle cell disease as well as febrile reactions to donor platelets were shown to enhance alloimmunisation in humans (Yazer et al., 2009; Fasano et al., 2015). Apart from one case report (Hata et al., 2013) to the best of our knowledge, the influence of infection-associated inflammation on red cell alloimmunisation in humans has not been reported.

In this nested case–control study, we quantified relative alloimmunisation risks for patients receiving red cell units during an infectious episode, according to the type of infection, its intensity, and the patient’s inflammatory response to it.

**Patients and methods**

**Study design and setting**

We performed a nested case–control study within a source population of previously non-transfused and non-alloimmunised patients in three university hospitals and three reference hospitals in the Netherlands. Using this design, we compared patients who developed red cell alloantibodies following transfusion with non-alloimmunised controls on the basis of supposed causal attributes, including various types of infections. Details on the source population, including its eligibility criteria, and our case–control study design have been previously published (Zalpuri et al., 2012a; Evers et al., 2016).

To summarize, patients were eligible if they received their first red cell transfusion during the study period in one of the participating hospitals, provided this transfusion was preceded by a negative antibody screen and followed by an antibody screen, hereby permitting evaluation of alloantibody development. The study period per hospital depended on electronic availability of the necessary data between 1 January 2005 and 31 December 2013 (for details, see Data S1). All red cell units were prepared by buffy-coat depletion of whole blood donations, subsequently filtered through a leucocyte depletion filter, and stored in saline, adenine, glucose, and mannitol (SAGM) for a maximum of 35 days (CBO, 2011).

A patient was defined as a case when developing a first, transfusion-induced red cell alloantibody directed against one of the following antigens: c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb, LuA, LuB, M, N, S or s. Anti-D immunised patients were not taken into consideration because we were unable to discriminate whether anti-D was caused by unmatched transfusions, or (mainly regarding fertile women) was due to recent anti-D administration in the context of a D-positive pregnancy or transfusion. Patients who formed antibodies, yet either lacked exposure to a (documented or assumed) antigen-positive red cell unit or expressed the antigen themselves (i.e., auto-immunised patients) were deemed ineligible. In addition, alloimmunised patients were excluded if their first-time alloantibody positive screen occurred within 7 days of the first mismatched transfusion, as these were more likely to represent boosting of earlier primary immunisations. By consulting the nationwide alloimmunisation registry (http://www.sanquin.nl/producten-diensten/diagnostiek/trix), we additionally excluded patients previously diagnosed with alloimmunisation in other hospitals. Considering the above-mentioned criteria, we specifically aimed to exclude previously alloimmunised patients, including pregnancy-induced immunisations in women. Finally, haemoglobinopathy patients and infants below 6 months of age were not included.

Each eligible case was matched to two randomly selected non-alloimmunised control patients based on the hospital and on the (lifetime) number of red cell transfusions received at the time of alloimmunisation. This ‘incidence-density sampling strategy’ ensured that controls were exposed to at least the same amount of transfusions as their matched cases and thus formed a representative sample of the source population (Rothman, 2007).

For all cases, we assumed that the last antigen-mismatched transfusion (the ‘Nth’ or implicated transfusion) preceding the first positive screen most likely elicited alloimmunisation. If this last mismatched transfusion could not be identified due to incomplete typing of donor units, we assumed the last non-tested unit preceding the first positive screen by at least 7 days to have elicited alloimmunisation. An ‘alloimmunisation risk period’ was then constructed, stretching from 30 days before up to 7 days after this implicated Nth transfusion. A similar risk period around the Nth transfusion was determined for the matched controls. The implicated transfusion and its alloimmunisation risk period are illustrated in Fig 1.

For all cases and controls, we recorded various clinical conditions during the alloimmunisation risk period.

The study protocol was approved by the Ethical Review Board at the Leiden University Medical Centre in Leiden and by the local board of each participating centre.

**First-formed red cell alloantibodies**

Patients in the Netherlands are routinely screen for red cell alloantibodies at a maximum of 72 h prior to red cell transfusion. According to the Dutch transfusion guideline (CBO, 2011), commercially available 3-cell screening panels are required to be homozygous positive for D, C, c, E, e, K, Fya, Fyb, Jka, Jkb, M, S and s. The presence of the K antigen in its heterozygous form is a minimum requirement. The presence of Cw, LuA, WrA, and KpA is not mandatory on commercially available screening cells (CBO, 2011). Antibody screening involves a three-cell panel using an indirect antiglobulin test [column agglutination technology from either BioRad (Cressier, Switzerland), or Ortho Clinical Diagnostics (Raritan, NJ, USA)]. If positive, screening is followed by subsequent
Data acquisition

We gathered routinely stored data on red cell transfusion dates, dates and results of antibody screens (including antibody specificity), patients’ date of birth, sex and leucocyte counts from the hospitals’ electronic laboratory information systems. In addition, we examined the medical charts of all cases and controls for the presence of various potential clinical risk variables during the alloimmunisation risk period, including dates of infection, the causative microorganisms, dates of fever (temperature $\geq 38.5^\circ C$), leucocyte counts, and C-reactive protein (CRP) values.

Bacterial infections comprised tissue-invasive infections (i.e. involving an anatomic site location) and bacteraemia (i.e. involving positive blood cultures).

Tissue-invasive bacterial infections were considered present when confirmed by either a positive blood or tissue culture, or when a suspected clinical infectious phenotype was supported by an overtly disease-specific radiographic anomaly e.g. a clear lobar consolidation on a chest x-ray in a patient with fever and cough. We categorized these infections into ‘mild’ or ‘severe’ according to their expected degree of systemic inflammation. Mild tissue-invasive bacterial infections included: routine (tip) cultures from central catheters, catheter-induced phlebitis, lower urinary tract infections, bacterial enteritis, skin and superficial wound infections, and upper respiratory tract infections. Severe tissue-invasive bacterial infections included: abscesses, intra-abdominal infections including spontaneously or secondarily infected abdominal fluid collections, arthritis, bursitis, myositis, fasciitis, infected haematoma, bacterial meningitis, deep wound or skin infections, endocarditis, mediastinitis, pericarditis, infected foreign material, lower respiratory tract infections, osteomyelitis, spondylodiscitis and upper urinary tract infections.

Bacteraemia were categorized according to their Gram-positive or Gram-negative causative microorganism.

For the qualification of a viral infection, a positive polymerase chain reaction (PCR) test demonstrating the replication of viral RNA or DNA was needed or, in case a PCR test was not performed, the clinical condition needed to be clearly virally induced, e.g. herpes labialis. Viraemia and disseminated viral zoster infections were defined as ‘disseminated viral infections’, in contrast to ‘local viral infections’, which were restricted to one anatomic site location.

Statistical analyses

The associations of various infections with the development of red cell alloimmunisation were evaluated using logistic regression analyses. For crude relative risk (RR) calculations, we conditioned on the matched variables, i.e. hospital and cumulative number of red cell units received.

For multivariate analyses, we also conditioned on measured confounders, taking into account that a confounder meets the prerequisites of being associated with the exposure (i.e. infections) in the source population, is (a marker for) a causal risk factor of the outcome (i.e. alloimmunisation) and is not in the causal pathway between the exposure and the outcome (Hernan et al., 2002; Middelburg et al., 2014). Consequently, we used the following strategy. First, we identified a subset of covariates to be confounders of a given determinant based on their observed association with the determinant within the source population (i.e. the non-alloimmunised controls). Such an association was defined as
a ≥3% difference in covariate presence between controls exposed and controls not exposed to the determinant. Covariates in the causal pathway between the determinant and the outcome were not considered as confounders (Hernan et al., 2002). Second, to be able to accurately control for confounders with low prevalences, we estimated a probability score for each determinant using logistic regression with the potential confounders as predictors (Brookhart et al., 2013). Third, to minimize bias due to missing data on the confounders, we used multiple imputation. Details on the used imputation model can be found in the Data S1 and Table S1. Finally, we evaluated the association between various types of infections and red cell alloimmunisation by subsequently entering the corresponding probability scores into the logistic regression model with alloimmunisation as the outcome and conditioning on the matched variables. We next assessed the association of level of CRP values and leucocytosis as possible markers of inflammation with red cell alloimmunisation. Leucocytosis was categorized as maximum measured leucocyte counts of 10–15, 15–20, 20–30 and >30 × 10^9/l, and referenced to normal counts (4–10 × 10^9/l). Maximum measured CRP values were categorized as 30–100, 100–200, 200–300 and >300 mg/l, and referenced to values ≤30 mg/l. Missing CRP and leucocyte values were multiply imputed using the same strategy as described above. While the likelihood that an increased inflammatory parameter has been recorded at least once increases with the number of measurements and thus with the duration of hospitalization, we repeated these analyses limited to parameters measured within the week following the implicated transfusion. As elevated CRP levels and leucocytosis reflect various clinical conditions preventing causal inferences, they are presented here only as unadjusted RR.

As anti-E, anti-C^w, anti-Le^a, anti-Le^b, anti-Lu^a, and anti-M can also form ‘naturally’ (e.g. directly in response to microbial epitope exposure (Reid et al., 2004), we evaluated a possible association between the presence of these antibodies and various types of infections using Pearson’s chi-square test. P-values <0.05 were considered to be statistically significant.

As we used an incidence-density sampling procedure to select controls (Rothman, 2007), we interpreted and present all odds ratios as RRs with 95% confidence intervals (95% CI).

### Sensitivity analyses

For some patients, the presence or absence of a certain type of infection could not be determined. These patients were left out of the corresponding analysis. Regarding severe bacterial infections, we performed a sensitivity analysis in which these patients were alternately assigned to exposure and non-exposure of this infection.

For patients with a suspected lower respiratory infection without conclusive or available cultures, we considered this infection to be due to a bacterial microorganism. Although viral or (rarely) fungal pathogens may cause pneumonia, bacterial microorganisms are the most common cause in Dutch hospitalised patients, with Streptococcus Pneumoniae and Haemophilus Influenzae alone representing 30–75% of causative pathogens (Wiersinga et al., 2012).

Finally, as contaminated blood cultures positive for coagulase-negative staphylococci (CNS) might dilute an existing effect of Gram-positive bacteraemia, we compared RRs for all Gram-positive bacteraemia with those for non-CNS Gram-positive bacteraemia.

### Results

Among 54 347 newly-transfused patients, 24 063 were considered eligible (Fig S1) of which 505 patients (2.1%) formed red-cell alloantibodies. Thirty-seven of these alloimmunised patients (7.3%) only received units of which the cognate antigen was unknown. For these, we assumed the last non-tested unit preceding the first positive screen to have elicited alloimmunisation.

General and clinical characteristics of the 505 cases and their 1010 matched controls during the alloimmunisation risk period are presented in Table I.

### Infections during the alloimmunisation risk period

Among all cases and controls, 473 patients were diagnosed with at least one infection during the alloimmunisation risk period. Of these, 417 suffered from bacterial infections, 53 from viral infections and 56 from fungal infections (Table II).

For 222 of 269 patients (82.5%) diagnosed with a severe tissue-invasive bacterial infection, the causal microorganism was identified by culture. For three of 53 virally-infected patients, no PCR test was performed during the alloimmunisation risk period. These patients were nevertheless included based on their clinical condition: one patient receiving an allogeneic stem cell transplantation with an outbreak of varicella zoster, one patient receiving chemotherapy for Burkitt lymphoma with herpes labialis, and one patient with liver cirrhosis due to a chronic hepatitis C infection.

Identified confounders per alloimmunisation determinant are presented in Tables SI and SIII. As illustrated, control subjects with viral infections were younger, had received more red cell units, and were more often leucopenic as compared to those without viral infections. These differences were probably due to a higher frequency of haematological malignancies and associated treatment modalities.

Missing data for any identified confounder per determinant was at a maximum of 3.1%. CRP values were not measured in 343 patients (22.6%) during the risk period (Table SI).

### The association between various types of infections and red cell alloimmunisation

The number of cases and controls diagnosed per type of infection are presented in Table III. For some patients, the
### Table I. Patient characteristics during the alloimmunisation risk period.

| Characteristics | Cases (N = 505) | Controls (N = 1010) | Missing data |
|-----------------|-----------------|---------------------|--------------|
| Male            | 237 (46-9)      | 568 (56-2)          |              |
| Age, years (median, IQR) | 67.0 (55-0–75-9) | 65.3 (51-6–75-1)   |              |
| Transfused in a university hospital | 232 (45-9) | 464 (45-9) |          |
| Cumulative (lifetime) number of red cell units up to implicated transfusion, median (IQR) | 4 (2–8) | 4 (2–8) |              |
| Single transfused, N (%) | 26 (5-1) | 7 (0-7) |              |
| Follow-up (days) up till last screen, median (IQR) | 92 (20–193) | 117 (10–609) |              |
| Cumulative number of red cell units during risk period, median (IQR) | 3 (2–6) | 4 (2–8) |              |
| Days transfused during risk period, median, (IQR) | 1 (1–3) | 2 (1–3) |              |
| ICU admission | 177 (36-5)     | 369 (35-0)          |              |
| Days at ICU, median (IQR) | 7 (2–18) | 7 (2–17) | 4            |
| Surgery | 267 (52-9) | 457 (45-2) | 2            |
| Thoracic including CABG | 61 (12-1) | 144 (14-3) |          |
| Abdominal | 100 (19-8) | 181 (17-9) |              |
| Back or spinal cord | 3 (0-6) | 11 (1-1) |              |
| Diabetes mellitus type 1 | 6 (1-2) | 7 (0-7) |              |
| Diabetes mellitus type 2 | 91 (18-0) | 176 (17-4) | 1            |
| Atherosclerosis* | 198 (39-5) | 314 (31-5) | 17           |
| Chronic obstructive airway disease† | 43 (8-5) | 89 (9-0) | 20           |
| Splenectomy (in past or during risk period) | 1 (0-2) | 19 (1-9) |              |
| Organ transplant | 4 (0-8) | 23 (2-3) |              |
| Liver cirrhosis | 13 (2-6) | 24 (2-4) | 2            |
| Haematological malignancy | 60 (11-9) | 210 (20-8) | 13           |
| Carcinoma | 112 (22-3) | 183 (18-2) | 7            |
| Chemotherapy | 66 (13-1) | 219 (21-8) | 6            |
| Radiotherapy | 15 (3-0) | 37 (3-6) |              |
| Leucopenia‡ | 102 (20-2) | 313 (31-0) | 41           |
| Haematopoietic stem cell transplantation (autologous or allogeneic, in past or during risk period) | 10 (2-0) | 63 (6-2) |              |
| Graft versus host disease (acute or chronic) | 4 (1-5) | 15 (0-8) | 3            |
| Immunosuppressant medication§ | 154 (30-9) | 423 (42-4) | 20           |
| GFR ≤ 30 ml/min¶ | 56 (11-1) | 149 (14-8) | 2            |
| Dialysis (either chronic or acute)¶ | 31 (6-1) | 98 (9-7) |              |

Values are n (%), unless otherwise stated. Numbers of patients for whom data on certain diagnoses and/or treatment modalities were not documented are presented as missing.

CABG, coronary artery bypass graft; GFR, glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range.

*Systemic or coronary atherosclerosis.
†Chronic asthma bronchiale or chronic obstructive pulmonary disease.
‡At least one measured leucocyte count below lower limit of normal.
§Medication under subcategory H02 (corticosteroids) or L04 (other immunosuppressants) within the Anatomical Therapeutic Chemical (ATC) classification index (WHO Collaborating Centre for Drug Statistics Methodology, 2016).
¶GFR below 30 ml/min during at least 1 week of the risk period (with GFR calculated using the Modification of Diet in Renal Diseases [MDRD] equation; Levey et al, 1999).
||Haemodialysis, peritoneal dialysis, or continuous veno-venous haemofiltration needed for at least 1 day during the risk period.

presence or absence of a certain type of infection could not be determined. The majority of these cases were due to an unestablished origin of the inflammatory condition (i.e. an infection or other inflammatory causes). In order to avoid misclassification, we omitted these patients from the corresponding analysis.

Mild bacterial infections were not associated with alloimmunisation. Patients with a severe tissue-invasive bacterial infection tended towards increased alloimmunisation risks [adjusted RR 1.34 (95% CI 0.97–1.85); Table III]. Relative risks increased to significance when these infections were accompanied with long-lasting fever [adjusted RR 3.06 (95% CI 1.57–5.96) with fever present for at least 7 days, Table IV]. The timing of fever i.e. occurring close to the implicated transfusion or at any time point during the risk period did not influence RRs (Table SIV). A sensitivity analysis on patients originally omitted from the analysis on severe bacterial infection (N = 47) did not change RRs (Table SV).

Given that alloantibodies against E, Cw,L ea,L eb,L ua, and M can also form ‘naturally’, [e.g. in response to microbial infection or other inflammatory causes). In order to avoid misclassification, we omitted these patients from the corresponding analysis.

Mild bacterial infections were not associated with alloimmunisation. Patients with a severe tissue-invasive bacterial infection tended towards increased alloimmunisation risks [adjusted RR 1.34 (95% CI 0.97–1.85); Table III]. Relative risks increased to significance when these infections were accompanied with long-lasting fever [adjusted RR 3.06 (95% CI 1.57–5.96) with fever present for at least 7 days, Table IV]. The timing of fever i.e. occurring close to the implicated transfusion or at any time point during the risk period did not influence RRs (Table SIV). A sensitivity analysis on patients originally omitted from the analysis on severe bacterial infection (N = 47) did not change RRs (Table SV).

Given that alloantibodies against E, Cw,L ea,L eb,L ua, and M can also form ‘naturally’, [e.g. in response to microbial epitope exposure rather than to transfusion-related red cell exposure (Reid et al, 2004)] we evaluated a possible
association between the induction of these antibodies and various infections using Pearson’s chi-square test. The distribution of alloantibodies known to also occur ‘naturally’ did not differ between patients with and without severe bacterial infections (Table V).

Interestingly, patients with a Gram-negative bacteraemia tended to demonstrate reduced alloimmunisation rates [adjusted RR 0.58 (95% CI 0.13–1.14)], while Gram-positive bacteraemia was not associated with red cell alloimmunisation (Table III). To exclude a potential dilution of
Table III. Association between (various types of) bacterial and viral infections and red cell alloimmunisation.

| Type of infection | Cases, N/total | Controls, N/total | RR (95% CI)* | Adjusted RR (95% CI)† | Excluded from analysis |
|-------------------|----------------|-------------------|---------------|------------------------|------------------------|
| Bacterial infections |                |                   |               |                        |                        |
| Tissue invasive infections | 129/486 | 228/961 | 1.17 (0.90–1.51) | 1.30 (0.98–1.74) | 68                     |
| Mild | 39/499 | 77/989 | 0.99 (0.66–1.49) | 1.08 (0.70–1.66) | 27                     |
| Severe | 100/490 | 169/978 | 1.22 (0.92–1.62) | 1.34 (0.97–1.85) | 47                     |
| Bacteraemia | 45/502 | 114/1003 | 0.75 (0.51–1.09) | 0.89 (0.59–1.36) | 10                     |
| Gram-positive | 34/502 | 83/1003 | 0.78 (0.51–1.20) | 1.08 (0.66–1.74) | 10                     |
| Gram-positive, non-CNS | 24/504 | 61/1009 | 0.82 (0.40–1.67) | 0.96 (0.56–1.65) | 2                      |
| Gram-negative | 13/505 | 44/1010 | 0.57 (0.30–1.09) | 0.58 (0.13–1.14) | 0                      |
| Viral infections |                |                   |               |                        |                        |
| All | 15/503 | 38/1003 | 0.72 (0.38–1.38) | 1.56 (0.75–3.25) | 9                      |
| Local | 7/503 | 20/1003 | 0.71 (0.29–1.74) | 1.80 (0.65–4.98) | 9                      |
| Disseminated | 10/505 | 20/1010 | 0.89 (0.40–2.02) | 2.41 (0.89–6.53) | 0                      |
| Fungal infections |                |                   |               |                        |                        |
| All | 12/501 | 44/1001 | 0.50 (0.25–0.99) | 0.60 (0.29–1.25) | 13                     |
| Candidaemia | 4/505 | 7/1010 | 1.19 (0.51–4.55) | 2.93 (0.54–15.89) | 0                      |
| Invasive aspergillus | 1/503 | 10/1004 | 0.17 (0.02–1.42) | 0.33 (0.03–3.28) | 8                      |

Patients for whom the presence or absence of a given infection could not be determined were excluded from the corresponding analysis. RR, relative risk; 95% CI, 95% confidence interval; CNS, coagulase negative staphylococcus.
*Adjusted for: number of transfused red cell units and hospital.
†Additionally adjusted for identified potential confounders (for details, see Table SIII).

Table IV. Infections and red cell alloimmunisation according to the presence of fever and its duration.

| Type of infection | Fever | Cases, N/total | Controls, N/total | RR (95% CI)* | Adjusted RR (95% CI)† |
|-------------------|-------|----------------|-------------------|---------------|------------------------|
| Severe bacterial infection |       | 390/490 | 809/978 | ref. | ref. |
| – | 17/490 | 48/978 | 0.72 (0.41–1.29) | 0.79 (0.44–1.43) | |
| + | 59/490 | 101/978 | 1.20 (0.84–1.71) | 1.33 (0.91–1.99) | |
| + | 24/490 | 20/978 | 2.67 (1.40–5.07) | 3.06 (1.57–5.96) | |
| Gram-positive bacteraemia |       | 468/502 | 921/1003 | ref. | ref. |
| – | 3/502 | 13/1003 | 0.51 (0.15–1.81) | 0.88 (0.34–3.28) | |
| + | 21/502 | 54/1003 | 0.72 (0.42–1.22) | 0.92 (0.52–1.61) | |
| + | 10/502 | 15/1003 | 1.29 (0.55–3.03) | 2.14 (0.84–5.41) | |
| Gram-negative bacteraemia |       | 492/505 | 966/1010 | ref. | ref. |
| – | 0/505 | 6/1010 | 0 (NC) | 0 (NC) | |
| + | 12/505 | 34/1010 | 0.70 (0.35–1.39) | 0.71 (0.35–1.45) | |
| + | 1/505 | 4/1010 | 0.52 (0.04–6.30) | 0.53 (0.04–6.62) | |
| Disseminated viral diseases |       | 495/505 | 990/1010 | ref. | ref. |
| – | 4/505 | 7/1010 | 1.14 (0.33–3.97) | 1.89 (0.50–7.15) | |
| + | 4/505 | 9/1010 | 0.61 (0.16–2.38) | 3.77 (0.64–22.24) | |
| + | 2/505 | 4/1010 | 1.12 (0.20–6.39) | 2.58 (0.37–17.82) | |

Only numbers of patients for whom the presence or absence of a given infection could be determined are presented. RR, relative risk; 95% CI, 95% confidence interval; NC, not computable.
*Adjusted for: number of transfused red cell units and hospital.
†Additionally adjusted for identified potential confounders (for details, see Table SIII).

an existing effect by contaminated blood cultures positive for CNS, we also evaluated the association of non-CNS Gram-positive bacteraemia with alloimmunisation. RRs from this analysis were identical to the originally calculated RRs. Any viral disease tended to be associated with increased red cell alloimmunisation incidences. The adjusted RR associated with disseminated viral infections was 2.41 (95% CI 0.89–6.53). The presence of fever did not influence RRs of viral infections (Table IV).
Discussion

This study, the first of its kind, in transfused patients suggests a possible association between infectious conditions and red cell alloimmunisation. Specifically, our observations suggest alloimmunisation to be influenced by the type and intensity of, and the patient’s inflammatory response to infections. In summary, severe (tissue-invasive) bacterial and viral infections were associated with increased incidences of alloimmunisation [RRs 1.34 (95% CI 0.97–1.85) and 2.41 (95% CI 0.89–6.53)]. In contrast, Gram-negative bacteraemia coincided with a twofold reduction of alloimmunisation risk [RR 0.58 (95% CI 0.13–1.14)].

Our findings certainly require additional confirmatory research. However, they seem to be biologically plausible and are in line with prior animal experiment observations (Hendrickson et al., 2006, 2007, 2008; Smith et al., 2012).

First, long-lasting fever with severe bacterial infections was associated with a substantially increased risk [RR 3.06 (95% CI 1.57–5.96)]. Here, persistence of fever could have reflected the most severe bacterial infections inducing a profound inflammatory response. Alternatively, or additionally, fever might have been due to other concomitant inflammatory conditions. Yet, both explanations are consistent with the ‘danger model’ (Matzinger, 1994) which postulates that an immune response is facilitated by pathogen-associated molecular patterns or structures released from cells undergoing stress (Matzinger, 1994; Gallucci & Matzinger, 2001; Kawai & Akira, 2010).

Second, although the 95% CI encompassing 1 (i.e. a null effect) warrants firm conclusions, we observed substantially increased alloimmunisation rates in patients with systemic viral infections. Murine experiments showed similar effects for poly(I:C) (Hendrickson et al., 2006, 2007, 2008; Smith et al., 2012), a synthetic viral RNA analogue that agonizes Toll-like receptor (TLR) 3 (Alexopoulou et al., 2001). These poly(I:C) effects were attributed to an increased dendritic cell consumption of transfused cells with upregulation of costimulatory molecules, and activation and proliferation of naïve CD4+ antigen-specific T-cells (Hendrickson et al., 2007, 2008). An existing molecular mimicry between certain viral peptides and CD4+ T-cell red cell antigen epitopes was also

Fungal infections, as well as candidaemia and invasive aspergillus infections separately, were associated with heterogeneous RRs not reaching significance (Table III).

Table V. Specificity and frequency of first-formed red cell alloantibodies according to the presence of various types of infections.

| All antibody specificity | All patients, N (%) | No infection, N (%) | Severe bacterial infection, N (%) | Viral infection (local and disseminated), N (%) | Gram-negative bacteraemia, N (%) |
|-------------------------|---------------------|---------------------|----------------------------------|-----------------------------------------------|---------------------------------|
| anti-C                  | 23 (4.0)            | 19 (5.2)            | 1 (0.9)                          | 0 (0)                                         | 1 (7.1)                         |
| anti-c                  | 41 (7.2)            | 25 (6.8)            | 8 (7.1)                          | 0 (0)                                         | 1 (7.1)                         |
| anti-E                  | 185 (32.3)          | 113 (30.7)          | 41 (36.4)                        | 4 (26.7)                                      | 5 (35.7)                        |
| anti-e                  | 5 (0.9)             | 5 (1.4)             | 0 (0)                            | 0 (0)                                         | 0 (0)                           |
| anti-K                  | 126 (22.0)          | 88 (23.9)           | 21 (18.6)                        | 3 (20.0)                                      | 6 (42.9)                        |
| anti-Cw                 | 19 (3.3)            | 10 (2.7)            | 4 (3.5)                          | 3 (20.0)                                      | 0 (0)                           |
| anti-Fyb                | 31 (5.4)            | 24 (6.5)            | 4 (3.5)                          | 1 (6.7)                                       | 0 (0)                           |
| anti-FyA                | 5 (0.9)             | 4 (1.1)             | 1 (0.9)                          | 0 (0)                                         | 0 (0)                           |
| anti-Jka                | 54 (9.4)            | 37 (10.1)           | 8 (7.1)                          | 3 (20.0)                                      | 0 (0)                           |
| anti-Jkb                | 7 (1.2)             | 4 (1.1)             | 2 (1.8)                          | 0 (0)                                         | 0 (0)                           |
| anti-Lea                | 7 (1.2)             | 2 (0.5)             | 4 (3.5)                          | 0 (0)                                         | 0 (0)                           |
| anti-Leb                | 3 (0.5)             | 1 (0.3)             | 1 (0.9)                          | 0 (0)                                         | 0 (0)                           |
| anti-LuA                | 32 (5.6)            | 19 (5.2)            | 9 (8.0)                          | 0 (0)                                         | 0 (0)                           |
| anti-LuB                | 0 (0)               | 0 (0)               | 0 (0)                            | 0 (0)                                         | 0 (0)                           |
| anti-M                  | 22 (3.8)            | 14 (3.8)            | 5 (4.4)                          | 1 (6.7)                                       | 0 (0)                           |
| anti-N                  | 1 (0.2)             | 0 (0)               | 0 (0)                            | 0 (0)                                         | 0 (0)                           |
| anti-S                  | 12 (2.1)            | 7 (1.9)             | 4 (3.5)                          | 0 (0)                                         | 1 (7.1)                         |
| anti-s                  | 0 (0)               | 0 (0)               | 0 (0)                            | 0 (0)                                         | 0 (0)                           |
| (possibly) natural occurring* | 268 (46.7) | 159 (43.2)          | 64 (56.6)                        | 8 (53.3)                                      | 5 (35.7)                        |

All antibodies 573 368 113 15 14
Number of patients 305 325 100 10 13

*Including: anti-E, anti-Cw, anti-Lea, anti-Leb, anti-LuA, and anti-M. No difference in distribution of (possibly) natural occurring alloantibodies was observed between patients with and without severe bacterial infections (P = 0.08), disseminated viral infections (P = 0.93), and Gram-negative bacteraemia (P = 0.41).
suggested, although observed effects in polyomavirus infected mice did not reach statistical significance (Hudson et al., 2010).

Although we did not analyse the association between latent viral infections and red cell alloimmunisation, these might also be relevant. In addition, the assessment of possible different effects of RNA and DNA viruses was prevented by low event numbers.

Third, we observed a twofold alloimmunisation incidence reduction during Gram-negative bacteraemia. Analogous to viral infections, these findings require confirmatory research. Yet, they again corroborate animal experiments showing significantly attenuated alloimmunisation responses upon lipopolysaccharide (LPS) pretreatment in mice (Hendrickson et al., 2008). LPS, an endotoxin in the outer cell membrane of Gram-negative bacteria, strongly stimulates innate immunity by agonizing TLR4 on macrophages and dendritic cells. Conversely, LPS is also implicated in a transient, possibly self-protective immune paralysis, known as LPS tolerance (Lauw et al., 2000; Weijer et al., 2002; Gould et al., 2004). Restimulation with LPS in this respect initiates blockage of CD4+ T cell functioning via impaired release of tumour necrosis factor α, interleukin (IL)12 and IL18 from monocytes and dendritic cells, together with a diminished upregulation of major histocompatibility complex class-II and costimulatory molecules (Mattner et al., 1998; Gould et al., 2004). While regulatory T cells selectively express TLRs (including TLR4), their LPS-induced proliferation might also contribute to the observed effects in both mice and humans (Caramalho et al., 2003). Finally, we cannot exclude an indirect role for Gram-negative bacteraemia on red cell alloimmunisation due to their common association with other modulators. Indeed, suppressed mitogenic B and T lymphocyte responses were observed following administration of antibiotics, including cephalosporins, an antibiotic class frequently used in the treatment of Gram-negative bacterial infections (Borowski et al., 1985; Pomorska-Mol et al., 2015).

In an intriguing contrast to the effects observed for Gram-negative bacteraemia, we did not observe any association between Gram-positive bacteraemia and red cell alloimmunisation. A common lower degree of acute inflammation evoked by gram-positive as compared to gram-negative bloodstream infections due to differing virulence mechanisms forms one hypothetical explanation (Wang et al., 2003; Gould et al., 2004; Abe et al., 2010).

Despite the RRs for fungal infections not differing significantly from those for Gram-negative bacteraemia, the heterogeneous RRs for individual fungal microorganisms and the lack of other supportive evidence prevent tentative inferences. Indeed, in contrast to our estimated RR, one report suggested neonatal alloimmunisation to be related to a disseminated histoplasmosis infection (Hata et al., 2013).

The ultimate goal of our study would be to establish an accurate alloimmunisation prediction model, serving as a practical tool for risk-based extended matching. Such a model would be most feasible when based on routinely measured patient parameters. In this perspective, we did not observe any association of the level of leucocytosis and CRP with alloimmunisation, possibly due to the multifactorial nature of these parameters. Other biomarkers, e.g. cytokine levels and immune cell subsets, might be better discriminative; however, they could not be evaluated in the current study.

Our study design, results and interpretations require additional remarks:

First, our incidence-density sampling strategy guarantees that selected controls were similarly exposed as their matched cases (Rothman, 2007). Hereby, our RRs are not influenced by transfusion burden, being a main determinant of red cell alloimmunisation (Zalpuri et al., 2012b; Evers et al., 2016).

Second, by identifying the implicated transfusion, we could study conditions present at that given time. As the duration of alloimmunisation modulation is currently unknown and will also probably differ per risk factor, we chose a seemingly large risk period to precede the implicated transfusion. Although one could argue that this strategy could possibly dilute some effects, on the other hand, it assures inclusion of most factors of influence at the time of exposure. For example, repeated LPS exposure might induce a state of tolerance persisting for up to 30 days (Cross, 2002). In addition, a recent study showed that poly(I:C) facilitates red cell alloimmunisation for at least 14 days with its maximum effect reached 7 days after administration (Elayeb et al., 2016). As a validation of our chosen risk period length, a sensitivity analysis on infections diagnosed during the week preceding or following the implicated transfusion did not change our conclusions (data not shown).

Similarly, only the duration of fever accompanying severe bacterial infections, rather than its timing in the risk period, affected alloimmunisation. As we aimed to target the most likely first initiation of an alloimmune response, we limited the risk period to the first 7 days following the implicated transfusion.

Third, actual lag periods per antigen-specific antibody are currently unknown. As such, our chosen lag period of 7 days might not completely have prevented the exclusion of patients demonstrating recall responses, including women immunised due to prior pregnancies. Direct antiglobulin tests were not performed on a routine basis shortly following transfusion and as such were of no help in identifying these patients. However, as non-RhD alloantibodies form in only 0.33% of first trimester pregnancies (Koelewijn et al., 2008), we believe that a substantial influence of previous pregnancies is unlikely. Moreover, erroneously considering a substantial amount of boosting reactions as primary alloimmunisation events would have biased our RRs towards the null-effect. Indeed, a sensitivity analysis in which we excluded the 53 patients in whom alloantibodies were discovered during the second week following their first antigen-incompatible transfusion did not substantially change RRs (data not shown). In conclusion, we believe the eventual bias due to our choice of the lag period to be small.
Fourth, to avoid invalid inferences due to misclassification, we did not define patients with a non-established aetiology of their inflammatory phenotype as exposed patients. For example, for a vascular compromised patient diagnosed with osteomyelitis, wound cultures positive for *Staphylococcus Aureus* might have represented normal skin flora colonization of a primary ischaemic wound. Consequently, the analysis on severe bacterial infections did not include this patient. A sensitivity analysis confirmed our results not to be affected by this possible misclassification bias.

In conclusion, our data suggest a potential risk modifying influence of infection-associated inflammation on red cell alloimmunisation in transfused patients. Alloimmunisation seems to be induced by severe bacterial or viral infections, but might be skewed towards protection in the presence of Gram-negative bacteraemia. Further confirmatory research is needed to ultimately identify the high-risk patient and, consequently, better target the allocation of more extensively matched red cell units.

**Acknowledgements**

The authors would like to thank James Zimring (Bloodworks Northwest, Seattle, USA) for critically reviewing our manuscript. Furthermore, we thank Bert Mesman and Herman Geerligs (Sanquin, Amsterdam) for reporting available antiscript. Furthermore, we thank Bert Mesman and Herman Northwest, Seattle, USA) for critically reviewing our manuscript.

**Disclosure of conflicts of interest**

The authors declare that they have no conflict of interest relevant to the work presented in this manuscript.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Data S1.** Study period per participating hospital and the used multiple imputation model.

**References**

Abe, R., Oda, S., Sadahiro, T., Nakamura, M., Hirayama, Y., Tateishi, Y., Shinohaki, K. & Hirasa, H. (2010) Gram-negative bacteraemia induces greater magnitude of inflammatory response than Gram-positive bacteraemia. *Critical Care*, 14, R27.

Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature*, 413, 732–738.

Borowski, J., Jakoubik, P. & Talarczyk, J. (1985) The influence of some cephalosporins on immunological response. *Drugs Under Experimental Clinical Research*, 11, 83–88.

Brookhart, M.A., Wyss, R., Layton, J.B. & Sturmer, T. (2013) Propensity score methods for confounding control in nonexperimental research. *Circulation: Cardiovascular Quality and Outcomes*, 6, 604–611.

Caramalho, I., Lopes-Carvalho, T., Ostler, T.D., Caramalho, I., Lopes-Carvalho, T., Ostler, T.D., Hillyer, C.D. & Zimring, J.C. (2006) Recipient inflammation affects the frequency and magnitude of immunogenicity in transfused red blood cells. *Transfusion*, 46, 1526–1536.

Harvey, A.R., Basavaraju, S.V., Chung, K.W. & Kuehnert, M.J. (2014) Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. *Transfusion*, 55, 799–718.

Hata, J.L., Johnson, M.S. & Booth, G.S. (2013) Neonatal alloimmunization: a rare case of multiple alloantibody formation in a patient with disseminated histoplasmosis. *Transfusion*, 53, 1140–1141.

Hendrickson, J.E., Desmaret, M., Deshpande, S.S., Chadwick, T.E., Hillyer, C.D., Roback, J.D. & Zimring, J.C. (2006) Recipient inflammation affects the frequency and magnitude of immunogenicity in transfused red blood cells. *Transfusion*, 46, 1526–1536.

Hendrickson, J.E., Chadwick, T.E., Roback, J.D., Hillyer, C.D. & Zimring, J.C. (2007) Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. *Blood*, 110, 2736–2743.

Hernandez-Diaz, S., Werler, M.M., Hendrickson, J.E., Chadwick, T.E., Roback, J.D., Hillyer, C.D. & Zimring, J.C. (2008) Discrete Toll-like receptor agonists have differential effects on alloimmunization to transfused red blood cells. *Transfusion*, 48, 1869–1877.

Hernan, M.A., Hernandez-Diaz, S., Werler, M.M. & Mitchell, A.A. (2002) Causal knowledge as a prerequisite for confounding evaluation: an
application to birth defects epidemiology. *American Journal of Epidemiology*, 155, 176–184.

Hudson, K.E., Lin, E., Hendrickson, J.E., Lukacher, A.E. & Zimring, J.C. (2010) Regulation of primary alloantibody response through antigenic exposure to a microbial T-cell epitope. *Blood*, 115, 3989–3996.

Kavai, T. & Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nature Immunology*, 11, 373–384.

Koelewijn, J.M., Vrijkotte, T.G., van der Schoot, C.E., Bonsel, G.J. & de Haas, M. (2008) Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. *Transfusion*, 48, 941–952.

Lasalle-Williams, M., Nuss, R., Le, T., Cole, L., Hassell, K., Murphy, J.R. & Ambruso, D.R. (2011) Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). *Transfusion*, 51, 1732–1739.

Lauw, F.N., ten Hove, T., de Jonge, E., van Deventer, S.J. & van der Poll, T. (2000) Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. *Infection and Immunity*, 68, 1014–1018.

Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. & Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine*, 130, 461–470.

Mattern, T., Flad, H.D., Brade, L., Rietschel, E.T., Zalpuri, S., Zwaginga, J.J. & van der Bom, J.G. (2012) Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. *Blood*, 119, 1566–1569.

TRIP (2014) Hemovigilance. TRIP annual report 2014. https://www.tripnet.nl/pages/en/documents/TRIP2014Hemovigilancedefinitie.pdf. Accessed March 31, 2016.

United Kingdom Blood Services (2013) Handbook of Transfusion Medicine, 5th edn. http://www-transfusionguidelines.org.uk/transfusion-handbook. Accessed March 11, 2016.